[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-skin-in-the-elderly\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-skin-in-the-elderly":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100633635","evaluation-of-oral-collagen-peptides-on-skin-barrier-function-in-women-100633635",false,"NCT07529249","Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women","Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women With Dry Skin","Inclusion Criteria:\n\n1. Participant having signed an Informed Consent Form (ICF);\n2. Healthy female Participant aged 45 to 70 years inclusive not followed by a healthcare practitioner for any skin disease;\n3. Participant with phototype II to IV according to the Fitzpatrick classification;\n4. Participant with dry skin measured on the cheeks (Tewameter, TEWL \\>15g\u002Fm²\u002Fh (skin barrier integrity) on back of the cheekbone)\n5. Female Participant of non-childbearing potential, defined as a woman without uterus and\u002For both ovaries, surgically sterile (at least 6 months prior to Screening visit) or post-menopausal (at least one year post cessation of menses);\n6. Female Participant of childbearing potential who has been using a highly effective birth control method for at least 1 month prior to Screening visit and agreeing to continue adequate contraception during the entire study period;\n\n   Highly effective birth control methods are:\n\n   \\- hormonal (combined or progestogen-only) contraception methods associated with inhibition of ovulation or intrauterine device; bilateral tubal occlusion since at least 3 months prior to Screening visit; vasectomised partner; True abstinence, i.e., refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the participant.\n7. Participant agreeing not to apply any cosmetic product (e.g. care cream, lotion, body milk) or drug on the face (except usual cleansing products) within 24 hours before the study visits;\n8. Participant agreeing to not apply cosmetic, medical, or aesthetic treatments out of the study protocol on the face and legs during the whole study duration;\n9. Participant affiliated to a health social security system (according to French Law).\n\nExclusion Criteria:\n\n1. Participant with a BMI ≤17 or ≥30 kg\u002Fcm²;\n2. Participant with any uncontrolled diseases such as diabetes, hypertension, hyperthyroidism or hypothyroidism;\n3. Presenting or having a history of eating disorder (e.g. anorexia, food allergy) or gastrointestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;\n4. Participant with an history of sleeve or bypass;\n5. Participant currently participating in another clinical study or being in an exclusion period of another clinical study;\n6. Participant with known or suspected hypersensitivity to any component(s) of the investigational products or to any ingredients of the vehicles (i.e., excipients);\n7. Participant with a known allergy to beef-derived products;\n8. Participant who has used collagen supplements, vitamin C, or other skin related nutraceuticals within the last 3 months\n9. Participant who started using prescription medications to treat skin conditions or other medications that affect the skin during the three months prior to the study\n10. Participant who has made significant lifestyle changes in the past three months (altering their diet, starting new exercises, or changing their skincare routines)\n11. Participant with skin abnormalities (e.g., scars, excessive hair, tattooing) or any dermatosis (e.g., psoriasis, eczema, acne vulgaris) on the face and legs which could interfere with the study;\n12. Participant impossible to contact in case of emergency;\n13. Participant who, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state);\n14. Participant who is in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomization;\n15. Protected participant as defined in the Articles of the French Public Health Code. Article 1121-7: person deprived of liberty by a judicial or administrative decision, or participant to psychiatric care, or person admitted to a health or social institution for purposes other than the research. Article 1121-8: adult person participant to a legal protection measure or unable to express his\u002Fher consent. Article L3212-1: person undergoing compulsory psychiatric treatment. Article L3213-1: person having a mental disorder that requires care and that which may compromise the safety of third persons or seriously undermine public order;\n16. Participant unable to communicate or cooperate with the Investigator;\n17. Participant having received 6000 euros indemnities for participation in clinical trials\u002Finvestigations in the 12 previous months, including participation in the present study (according to French Law);",true,"FEMALE","45 Years","70 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical study aims to determine whether taking two different doses of collagen-derived peptides for three months improves facial skin barrier integrity in women with dry, sensitive skin, compared with a placebo.",[28,29,30,31],"Dry Skin","Sensitive Skin","Dry Skin in the Elderly","Dietary Supplement",[33,34,35,36,37],"cpcad","skinpharma","dry skin","dietary supplement","sensitive skin","RECRUITING","2026-05-07",{"date":41,"type":42},"2026-05-12","ACTUAL",{"date":44,"type":22},"2026-04",{"date":46,"type":22},"2026-09",{"name":48,"class":49},"Centre de Pharmacologie Clinique Applique a la Dermatologie","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100603242","a-clinical-observational-study-evaluating-the-efficacy-of-cerave-neuroceramide-intensive-repair-body-lotion--100603242","NCT07133971","A Clinical Observational Study Evaluating the Efficacy of Cerave Neuroceramide Intensive Repair Body Lotion .","A Clinical Observational Study Evaluating the Efficacy of Cerave Neuroceramide Intensive Repair Body Lotion in Improving Dry Skin in the Elderly","Inclusion Criteria:\n\n* Individuals with moderate to severe skin dryness as assessed by a clinician (ODS score of 2 or 3)\n* Individuals with moderate to severe self-reported skin itching as assessed by a clinician (NRS ≥ 1)\n* Individuals aged 55 years and older\n* Open to patients with one or more of the following conditions:\n\n  1. History of atopic dermatitis;\n  2. Currently using a stable medication regimen prescribed and monitored by a physician (ongoing use), where the medication has side effects causing skin dryness (e.g., statins, calcium channel blockers, diuretics, antiplatelet agents, ACE inhibitors, beta-blockers, adrenergic receptor agonists, immunosuppressants, etc.);\n  3. Patients with systemic diseases associated with dryness (diagnosed and managed by a physician), such as diabetes, hyperthyroidism, hypothyroidism, or hemodialysis.\n* Voluntarily participate in the trial, understand and agree to sign the informed consent form, and agree to follow the study protocol throughout the study period, including using the study-provided products, not using other similar products, completing a diary, and attending regular follow-up visits as required by the trial.\n\nExclusion Criteria:\n\n* Individuals with a history of allergy, allergic reaction, or hypersensitivity to any component of the study product (Cerave Neuroceramide Moisturizing Repair Body Lotion);\n* Individuals with a history of allergic contact dermatitis secondary to the use of moisturizing products;\n* Individuals with any clinical manifestations or other conditions at the treatment site that the physician deems may affect the evaluation or results of the study product;\n* Individuals who are unable or unwilling to attend all study visits and adhere to the treatment regimen;\n* Individuals who have participated in any other drug clinical studies within the past 3 months prior to the start of the trial.","ALL","55 Years",{"count":61,"type":22},210,"OBSERVATIONAL","This study is a single-center observational clinical study aimed at evaluating the impact of Cerave Neuroceramide Moisturizing Repair Body Lotion on the quality of life, improvement in skin condition, and satisfaction with the product experience among individuals with moderate to severe dry skin associated with aging. The study plans to recruit approximately 210 male or female participants aged 55 years or older with moderate to severe skin dryness in the affected areas (accounting for a dropout rate and protocol violation rate of no more than 5%), and will screen participants based on inclusion and exclusion criteria to ensure that at least 200 participants complete the study. Participants entering this study will be categorized based on ODS and NRS scores into: moderate or severe skin dryness (moderate-grade 2, severe-grade 3), with the sample size ratio between moderate and severe groups maintained at 1:1. This study will last for 4 weeks and include 2 visits. Visits will be conducted at baseline (T0) and week 4 (T4w). The window period for the week 4 (T4w) visit is ±2 days. This study does not involve randomization. All study participants will use Cerave Neuroceramide Moisturizing Repair Body Lotion on areas of skin dryness.",[30],"NOT_YET_RECRUITING","2025-08-20",{"date":68,"type":42},"2025-08-21",{"date":70,"type":22},"2025-08-22",{"date":72,"type":22},"2026-01",{"name":74,"class":75},"ChinaNorm","INDUSTRY"]